October 20, 2005 -- Proposed diabetes drug Pargluva came under fire for causing cardiovascular problems; StemCells can begin a Phase I test of its neural stem cell treatment; privately held Cardium Therapeutics will merge with Aries Ventures in a complicated deal that involves a new drug and new financing; Chelsea Therapeutics reported positive data on its oral treatment for autoimmune diseases; the FDA approved a Novo Nordisk medication for type 1 diabetes in children; and Pfizer hit a 52-week low after reporting weaker than expected revenues. The Centient Biotech 200™ gave back the gains from yesterday, ending 67 points lower at 3637, a drop of 1.81. More details...
